相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Interferon-1a and-1b for patients with multiple sclerosis: updates to current knowledge
Uwe Klaus Zettl et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson et al.
LANCET NEUROLOGY (2018)
Is There a Relationship Between Multiple Sclerosis and Epilepsy? If So What Does It Tell Us About Epileptogenesis?
Alison Pack
Epilepsy Currents (2018)
Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar
Dirk Deleu et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis
Tomas Olsson et al.
NATURE REVIEWS NEUROLOGY (2017)
Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs
Luca Degli Esposti et al.
NEUROLOGICAL SCIENCES (2017)
Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality
Anja Thormann et al.
NEUROLOGY (2017)
Clinical, Radiological and Electrophysiological Comparison of Immunomodulatory Therapies in Multiple Sclerosis
Gencer Genc et al.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY (2017)
MRI in the assessment and monitoring of multiple sclerosis: an update on best practice
Ulrike W. Kaunzner et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2017)
MRI for multiple sclerosis diagnosis and prognosis
Sven Schippling
NEURODEGENERATIVE DISEASE MANAGEMENT (2017)
Factors associated with adherence to immunomodulator treatment in people with multiple sclerosis
Nair Assunta Antonia Corso Camara et al.
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature
David Kavanagh et al.
BLOOD (2016)
Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15
Ludwig Kappos et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview
Ruth Ann Marrie et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Epidemiological study of multiple sclerosis in La Rioja
M. Bartulos Iglesias et al.
NEUROLOGIA (2015)
Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study
A. Saiz et al.
NEUROLOGIA (2015)
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview
Ruth Ann Marrie et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Postmarketing Safety Profile of Subcutaneous Interferon Beta-1a Gven 3 Times Mekly: A Retrospective Administrative Claims Analysis
Meredith Y. Smith et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2015)
Comorbilidad en esclerosis múltiple y su abordaje asistencial
Bonaventura Casanova Estruch
MEDICINA CLINICA (2015)
A 10-year follow-up of a population-based study of people with multiple sclerosis in Stockholm, Sweden: Changes in health-related quality of life and the value of different factors in predicting health-related quality of life
Charlotte Chruzander et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Thrombotic Microangiopathy Associated with Interferon Beta
David Hunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Clinical features of 314 patients with relapsing-remitting multiple sclerosis
Jorge Nogales-Gaete et al.
REVISTA MEDICA DE CHILE (2014)
Association between multiple sclerosis and epilepsy: large population-based record-linkage studies
Alexander N. Allen et al.
BMC NEUROLOGY (2013)
Scoring treatment response in patients with relapsing multiple sclerosis
M. P. Sormani et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis
Tomas Kalincik et al.
PLoS One (2013)
Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis
Julien Mahe et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
Multiple Sclerosis: Needs analysis and quality of life of affected people and their environment
Jose Carron et al.
REVISTA ESPANOLA DE DISCAPACIDAD-REDIS (2013)
Viability of autoantibody-targets: How to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis
Marie Cathrin Mayer et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2012)
Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence
G. Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Thrombotic microangiopathy associated with use of interferon-beta
Teresa Olea et al.
INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE (2012)
Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: escalating therapy
A. Garcia Merino et al.
NEUROLOGIA (2010)
Real-Life Impact of Early Interferonβ Therapy in Relapsing Multiple Sclerosis
M. Trojano et al.
ANNALS OF NEUROLOGY (2009)
Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study
S. A. Gauthier et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
Measures in the first year of therapy predict the response to interferon β in MS
J. Rio et al.
MULTIPLE SCLEROSIS (2009)
分享论文
